Dr Gaurav Bhutada, Dr Kaushika Rautray, Dr Sourya Acharya, Dr Samarth Shukla


AIM: To study the distribution and pattern of anemia and other hematological abnormalities in cases of cirrhosis of liver.METHODS: This cross sectional study was conducted in AcharayaVinobhaBhave Rural Health, Wardha. A total of 30 cirrhotic patients were studied in 6 months. Thirty patients with cirrhosis of liver were included in this study. Meticulous clinical examination was done. Relevant hematological investigations were carried out and patients were treated according.RESULTS:The study includes 30 cases of cirrhotic patients.In this study 73.3% constituted male patients 26.67% constituted female patients.As per sex wise distribution, cirrhotic cases was highest in males i.e. 22 cases (73.3%), as compare to females,8 cases (26.6%). The most common age group was 31-40years. The most common clinical manifestation presented was ascites i.e 29 cases out of 30(96.67%) and melena being the least common i.e only 2 cases out of 30 cases (6.67%).83.33%  of the patients were found to be have anemia (Hb less than 11gm%), out of which 40% ad Hb less than 7gm%.Out of a total of 30 patients , 8 (26.66%)had normal MCV, 11 (36.66%)  had macrocytosis and 11(36.66%) had microcytosis. 10 (33.33%) had leucopenia, which can be due to hypersplenism.% had thrombocytopenia CONCLUSION: anemia is the most common hematological abnormality in cirrhosis. The etiology is multifactorial. So it is imperative to correct the etiological factor for anemia and other hematological abnormalities


cirrhosis, anemia , hematological abnormalities, thrombocytopenia, leucopenia and hypersplenism.

Full Text:



Melato M, Sasso F, Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. ZentralblPathol 1993; 139: 25–30.

Graudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med 1991; 230:165–171.

Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733–746.

Mathers C, Lopez A, Murray C. The burden of disease and mortality by condition: data, methods, and results for 2001. In: Lopez A, Mathers C, Ezzati M, et al, editors. Global burden of disease and risk factors.Washington (DC): Oxford University Press and the World Bank; 2006. p. 45–93.

Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.

Mehta AB, McIntyre N .Hematological disorders in liver disease. Forum (Genova). 1998 Jan-Mar;8(1):8-25.

Kimber C, Deller DJ, Ibbotson RH, and Lander H. The mechanism of anaemia in chronic liver disease. Quarterly Journal of Medicine, 1965; 34: 33-64.

Means RT and Krantz S. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood,1992;80:1639-47.

Sheila Sherlock. Disease of Liver, Biliary system 11th edition, 25 Oct 2007.

Haussinger D, Bircher J, Benhamou J, McIntyre N, Rizzetto M, Rodes J, Oxford text book of hepatology II edition Oxford University Press, Oxford, 1999, pg 325.

Sheehy TW and Berman A. The anaemia of cirrhosis. Journal of Laboratory and Clinical Medicine, 1960; 56: 72-82

McHutchison, J.G., M.P. Mannsand and D.L. Longo. Definition and management of anemia patients infected with hepatitis C virus. Liver Int., 26: 389-398.

Liangpunsakul S, Sithat M, Ulmer B, et al. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sciences. 2003;326:111–16.

Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease:reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727–33

Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis p-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology 2001; 48: 818–22.

Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. ThrombHaemost 1998;79: 1106–10.

Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795–801.

Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis:kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 1993; 20: 123–9

Schmidt KG, Rasmussen JW, Bekker C, Madsen PE. Kinetics and in vivo distribution of 111-in-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol 1985; 34: 39–46.

Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982; 99:217–30.

Qamar AA, Grace ND, Groszmann RJ. Incidence , prevalence , and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clinical gastroenterohepatology 2009;7(6):689-695.

Bahour FN, Tehran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease.Am J Gastroenterol.2009;95(10):2936-2939.

Panzer S, Seel E, Brunner M. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77: 513–7.


  • There are currently no refbacks.